Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.

Koos P J van Dam,Laura Hogenboom,Eileen W Stalman,Laura Y L Kummer,Maurice Steenhuis,Jim B D Keijser,Anja Ten Brinke,S Marieke van Ham,Taco W Kuijpers,Theo Rispens,Luuk Wieske,Filip Eftimov,Eva M Strijbis,Joep Killestein,Zoé L E van Kempen

Frontiers in neurology（2022）

引用 1|浏览6

暂无评分

摘要

In patients with MS without anti-CD20 therapies, SARS-CoV-2 infection before vaccination increases humoral responses after the first vaccination, similar to the healthy controls. In patients with MS treated with ocrelizumab (convalescent and non-convalescent), humoral responses remained low.

查看译文

关键词

COVID-19,SARS-CoV-2,disease modifying treatment,humoral response,multiple sclerosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要